What are the two compounds, BPC-157 and TB-500?
BPC-157 stands for Body Protection Compound-157. It is a synthetic 15-amino-acid peptide derived from a sequence found in human gastric juice protein. The majority of BPC-157 research has been conducted in rodent models by researchers at the University of Zagreb, examining its proposed effects on tissue recovery, nitric oxide signaling, collagen synthesis, and gastrointestinal mucosal support. There are no large-scale, randomized, controlled human clinical trials on BPC-157 published to date.
TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring 43-amino-acid protein involved in actin polymerization, cell migration, and angiogenesis. The active segment of Thymosin Beta-4 is its actin-binding domain; TB-500 is designed to deliver that domain in a smaller synthetic form. Thymosin Beta-4 research is more established than BPC-157 research in some respects — it has been studied in cardiac injury models and wound healing — but TB-500 specifically as a compounded peptide also lacks human clinical trial data.
Why would you use intranasal delivery for BPC-157 and TB-500?
Intranasal peptide delivery has been an active area of pharmaceutical research because the nasal mucosa offers several potential advantages over oral and injectable routes for certain compounds:
- Bypass of first-pass metabolism: Peptides administered nasally are absorbed through the nasal mucosal epithelium and can enter systemic circulation without passing through the hepatic portal system, where many peptides are rapidly degraded.
- Potential CNS access via the olfactory route: The olfactory nerve and trigeminal nerve pathways in the nasal cavity offer a potential anatomical route for drug transport to the brain, bypassing the blood-brain barrier to some extent. This route has been studied for a range of neurologically active compounds.
- Needle-free administration: For patients averse to subcutaneous injection, intranasal delivery offers a non-invasive alternative that some find more adherence-friendly.
The appeal of combining BPC-157 and TB-500 in a single intranasal formulation is that both peptides have proposed systemic tissue-supportive properties — the theory being that a combined preparation might address multiple recovery-related pathways simultaneously. That rationale is speculative in the absence of controlled human data on either compound via the intranasal route.
The intranasal rationale is borrowed from drug-delivery science — no published study has tested a BPC-157/TB-500 nasal spray in animals or humans.
What does the preclinical research actually show about these peptides?
BPC-157 has been studied via multiple administration routes in animal models, including oral, subcutaneous, intraperitoneal, and topical. Some animal studies have found systemic effects even with oral BPC-157, which researchers have attributed in part to the peptide’s relative stability in the gastric environment — unsurprising given its origin as a gastric-derived sequence. This oral bioavailability signal is biologically interesting and distinguishes BPC-157 from many other peptides that are more fully degraded in the GI tract.
TB-500 / Thymosin Beta-4 has been studied in models of cardiac, corneal, and skin injury. Injectable forms have shown tissue-supportive signals in animal models, and some early-stage human research on Thymosin Beta-4 in cardiac contexts has been conducted.
However: published intranasal studies specifically on BPC-157 or TB-500 are not available in the peer-reviewed literature. The combination formulation (BPC-157 + TB-500 in a single nasal spray) has not been the subject of any controlled human or animal study that is publicly available. What circulates about it in online communities is primarily anecdotal and extrapolated — not clinical-trial data.
What is the regulatory status, and what does it mean for access?
BPC-157 is classified by the FDA as a Category 2 bulk drug substance, meaning licensed US compounding pharmacies are not currently permitted to prepare or dispense it in any form — including nasal spray. This classification reflects the FDA’s assessment of the current evidence base and the adequacy of safety data for human use.
TB-500 (synthetic Thymosin Beta-4 fragment) occupies a different but also unsettled regulatory position. Neither compound is currently accessible through the licensed 503A compounding pathway that governs peptide therapy at PepScribe.
Products available through unregulated online vendors, labeled as “research use only” or sold without a clinician prescription, are not subject to the purity, potency, and sterility standards of licensed US compounding pharmacies. Purchasing from such sources carries substantial and unquantifiable risks.
What is available now through legitimate channels?
If your interest in BPC-157/TB-500 nasal spray is rooted in recovery support, connective tissue maintenance, or overall physical resilience, there are Tier 1 peptides available through licensed US 503A compounding pharmacies under a clinician prescription:
- Sermorelin — a GHRH analogue that supports the body’s own growth hormone secretion. Published human research, Category 1 status, available through licensed compounders with a prescription.
- NAD+ — a coenzyme that plays central roles in cellular energy metabolism and repair pathways. Available through licensed US 503A compounders.
A clinician consultation will match you to the therapeutically appropriate option based on your specific goals and health history — not a peptide trending in online forums.
Frequently asked questions
What is BPC-157/TB-500 nasal spray?
BPC-157/TB-500 nasal spray refers to a combination of two peptides — BPC-157 (Body Protection Compound-157) and TB-500 (a synthetic fragment of Thymosin Beta-4) — formulated for intranasal delivery. This combination is not an FDA-approved product; it has been discussed primarily in research and peptide community contexts.
What is the compounding status of BPC-157 and TB-500 nasal spray?
Neither BPC-157 nor TB-500 is an FDA-approved drug, and neither is currently on FDA's 503A Bulks List, in any form including nasal spray. FDA's Pharmacy Compounding Advisory Committee met to review both compounds on July 23-24, 2026, and FDA has not issued a final determination. Whether any therapy is appropriate is a clinical decision, so talk to a PepScribe clinician about your goals.
What does the research say about intranasal peptide delivery?
Intranasal delivery can allow peptides to reach systemic and potentially central nervous system circulation via the nasal mucosa, bypassing first-pass metabolism. The olfactory pathway has been a subject of research for CNS-targeted peptide delivery. However, published human clinical trial data specifically on intranasal BPC-157 or TB-500 does not exist.
Are there legally available alternatives for tissue recovery support?
Yes. Sermorelin and NAD+ are Tier 1 peptides available through licensed US 503A compounding pharmacies with a clinician prescription. Both have a clearer regulatory standing and published human research. A clinician can evaluate whether they align with your recovery goals.
Is it safe to buy BPC-157 or TB-500 nasal spray online?
Unregulated online vendors selling these compounds operate outside the licensed compounding framework. Products from unregulated sources carry significant risks related to purity, sterility, accurate dosing, and undisclosed contaminants. PepScribe strongly advises against obtaining any peptide from unverified vendors.
